{
    "organizations": [],
    "uuid": "ee58775f8ec6d8c87b51fbb6477f1f681cbb5efd",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-astrazeneca-says-prolonging-treatm/brief-astrazeneca-says-prolonging-treatment-with-brilinta-after-1-yr-reduces-risk-of-major-adverse-cardiac-events-by-19-pct-idUSFWN1PX025",
    "ord_in_thread": 0,
    "title": "BRIEF-AstraZeneca Says Prolonging Treatment With Brilinta After 1-Yr Reduces Risk Of Major Adverse Cardiac Events By 19 Pct",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 7 (Reuters) - AstraZeneca Plc:\n* ‍BRILINTA SIGNIFICANTLY REDUCES CV EVENTS AND CORONARY DEATH BEYOND ONE YEAR IN HEART ATTACK SURVIVORS WITH MULTI-VESSEL DISEASE​ Further company coverage:\n ",
    "published": "2018-02-07T15:25:00.000+02:00",
    "crawled": "2018-02-09T05:35:27.002+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "astrazeneca",
        "plc",
        "significantly",
        "reduces",
        "cv",
        "event",
        "coronary",
        "death",
        "beyond",
        "one",
        "year",
        "heart",
        "attack",
        "survivor",
        "company",
        "coverage"
    ]
}